Biotechnology company focusing on psychedelic therapies for treatment HAVN Life Sciences Inc. (CSE: HAVN) (OTCMKTS: HAVLF) announced having entered into a definitive agreement to acquire all outstanding securities of Spore Life Sciences Inc. on conditions drafted on the definitive agreement.
Spore Life Sciences is a direct-to-consumer wellness brand focusing on merging the power of magic mushrooms with the demands of modern lifestyle, the company has its headquarters in Toronto, Canada.
Spore Life Sciences enjoys a significant consumer base in the United States of over 110,000 Spore customers and around 40,000 subscribers as of the end of November 2021. Currently the company has average monthly sales of over $1 million.
“With this Definitive Agreement, HAVN Life is looking to strengthen its position as a leader in brain health focused nutritional supplements. Upon completion of the Acquisition, we will add these high quality formulations to the HAVN Life natural health product portfolio,” says the CEO of HAVN Life Sciences, Tim Moore.
On the other side, the co-founder, CEO and president of Spore Life, Michael Zavet, says this acquisition will bring in 9 additional formulations under the HAVN Life retail brand and this will add to the company’s growing selection of natural health products which support overall health and cognitive function.
“We are very excited about this potential partnership and believe that HAVN Life’s strong leadership team in the psychedelic space, its experience with natural health products, and network in retail are extremely complementary to our business. We are also excited to support HAVN’s psychedelic endeavors through our digital marketing channels and large customer base,” said Zavet.
